Jiangsu Vcare's Class 1 Innovative Drug VC005 Tablets Receives Clinical Trial Approval
Published Time:
2021-08-16 17:38
Source:
In August 2021, VC005 tablets, an innovative drug developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received clinical trial approval from the NMPA for the indication of inflammatory bowel disease (IBD), with clinical trials set to begin shortly.
VC005 tablets is a novel, highly selective JAK1 inhibitor independently developed by Jiangsu Vcare. It effectively inhibits inflammatory targets such as TYK2 while simultaneously suppressing immune cell-mediated cytotoxicity and immune responses. It exhibits weaker inhibitory activity against JAK2 and JAK3, demonstrating favorable compound selectivity.
The JAK-STAT signaling pathway plays a crucial role in the pathogenesis of diseases like IBD. Marketed oral JAK inhibitors, due to their lower selectivity, inhibit JAK1 while also affecting targets like JAK2 and JAK3. This has led to the clinical manifestation of severe adverse reactions, including anemia, infections, dyslipidemia, and malignancies, prompting the FDA to issue boxed warnings. As safety concerns regarding JAK inhibitors have been frequently reported, regulatory agencies have become increasingly cautious regarding the expansion of indications and the review of new drug applications for this class. Since the first half of 2021, the FDA has repeatedly delayed review decisions for JAK inhibitors, drawing significant attention from the biopharmaceutical industry.
The development of VC005 tablets is based on a differentiated strategy, specifically addressing the above-mentioned issues from the initiation and design stages of the project. Preclinical studies have confirmed that compared to drugs targeting the same pathway, VC005 exhibits a lower effective dose, higher tolerated dose, and fewer side effects in animal models, suggesting potential dual advantages in both safety and efficacy. It holds promise to become a globally leading therapeutic option for autoimmune and inflammatory diseases.
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn